Verona Integron-Encoded Metallo-β-Lactamase (VIM)-Producing Carbapenem-Resistant Pseudomonas aeruginosa Infections Associated with Invasive Medical Procedures in Tijuana, Mexico
March 14, 2019
Lee Samuel
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention
1600 Clifton Road, NE
Atlanta, Georgia 30333
Phone: (404) 718-1616
Email: [email protected]
1. Respondent Universe and Sampling Methods 2
2. Procedures for the Collection of Information 2
3. Methods to maximize Response Rates and Deal with No Response 2
4. Tests of Procedures or Methods to be Undertaken 2
5. Individuals Consulted on Statistical Aspects and Individuals Collecting and/or Analyzing Data 2
Respondents include individuals who had surgery since January 1, 2019 at Facility 1 in Tijuana, Mexico and are at highest risk for developing VIM-CRPA infection and/or receiving ongoing treatment for surgical site infection in the U.S. healthcare system. An additional 550 U.S. residents who had surgery at Facility 1 in Tijuana, Mexico between August 1 and December 31, 2018 are at lower risk for developing new VIM-CRPA infection but may be surveyed if interviews of more recent exposed individuals suggest high rates of infection and hospitalization that could facilitate spread of this multidrug-resistant organism in the U.S. healthcare system. No additional individuals will be included in the activity.
Individuals collecting and analyzing data are public health professionals based at state and local health departments and CDC and are experienced in administering public health surveys. Individuals in performing analysis are expert in the primarily descriptive statistics that will be performed. As no high-level statistical methods are used in this data collection or analysis, no statisticians were consulted.
File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
File Modified | 0000-00-00 |
File Created | 0000-00-00 |